IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class
Debt / NOTE 1.500% 6/1
Number of holders
19
Total 13F principal, excl. options
195,546,000
Principal change
-2,607,834
Total reported value, excl. options
$222,198,820
Value change
-$9,175,256
Number of buys
6
Number of sells
-8
Price
$1.14

Significant Holders of IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1 as of Q4 2021

23 filings reported holding 46333XAH1 - IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1 as of Q4 2021.
IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1 has 19 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of $195,546,000 of principal .
Largest 10 bondholders include CITADEL ADVISORS LLC ($68,788,000 of principal), CAMDEN ASSET MANAGEMENT L P /CA ($40,725,000 of principal), UBS ASSET MANAGEMENT AMERICAS INC ($19,912,000 of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($11,903,000 of principal), CALAMOS ADVISORS LLC ($9,500,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($9,181,000 of principal), AQR Arbitrage LLC ($8,100,000 of principal), Jefferies Group LLC ($7,450,000 of principal), PUTNAM INVESTMENTS LLC ($7,270,000 of principal), and Polar Asset Management Partners Inc. ($7,000,000 of principal).
This table shows the top 19 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.